Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Mayo Clinic

Sites in Phoenix & Scottsdale, AZ

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 12:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
609
Shown on this page
12
Current sort
Recently updated
Campus scope
Mayo Clinic, Phoenix & Scottsdale, AZ
Additional filters apply within this campus.

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

Filter and sort this campus

These controls apply only within Mayo Clinic, Phoenix & Scottsdale, AZ. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 469–480 of 609 matching trials with a site at Mayo Clinic, Phoenix & Scottsdale, AZ.
Indexed local directory records.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Active, not recruiting No phase listed Observational Results available

CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

NCT03933826
Site status not listed — check the official record
View directory record Official record
Conditions
Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
570 participants
Timeline
2019 – 2029
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 13, 2026, 6:43 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

NCT03038672
Site status not listed — check the official record
View directory record Official record
Conditions
ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Mucocutaneous Ulcer, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Large B-Cell Lymphoma With 11q Aberration, Large B-Cell Lymphoma With IRF4 Rearrangement, Plasmablastic Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Primary Effusion Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Gray-Zone Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Lymphomatoid Granulomatosis, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Gray-Zone Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions
Nivolumab, Varlilumab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 15, 2026, 6:34 AM EDT
Active, not recruiting Not applicable Interventional Results available

Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS

NCT02926911
Site status not listed — check the official record
View directory record Official record
Conditions
DCIS, Ductal Carcinoma in Situ
Interventions
Active Monitoring, Surgery
Other
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
40 Years to 99 Years · Female only
Enrollment
997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
141
States / cities
Anchorage, Alaska • Phoenix, Arizona • Duarte, California + 117 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 14, 2026, 1:42 AM EDT
Active, not recruiting Not applicable Interventional

CREST: Capsular Repair During Hip Arthroscopy

NCT03372564
Site status not listed — check the official record
View directory record Official record
Conditions
Hip Arthroscopy
Interventions
Hip Capsule Repair
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2040
U.S. locations
3
States / cities
Scottsdale, Arizona • Westmont, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 14, 2026, 6:23 PM EDT
Recruiting Not applicable Interventional

Pulmonary Rehabilitation for Rural Patients With COPD

NCT06847061
Status at this site: Recruiting
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD
Interventions
Pulmonary rehabilitation program
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 29, 2026, 2:09 AM EDT
Recruiting Phase 3 Interventional

Neoadjuvant Darovasertib in Primary Uveal Melanoma

NCT07015190
Status at this site: Recruiting
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Darovasertib, Primary Local Therapy
Drug · Procedure
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
35
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 14, 2026, 6:09 PM EDT
Recruiting Phase 2 Interventional

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

NCT01042379
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Angiosarcoma, Breast Cancer, Breast Neoplasms, Breast Tumors, Early-stage Breast Cancer, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor Negative Tumor, Hormone Receptor Positive Tumor, Locally Advanced Breast Cancer, TNBC - Triple-Negative Breast Cancer
Interventions
ABT-888, AMG 386 and Trastuzumab, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, ARV-471, ARV-471 + Abemaciclib, ARV-471 + Letrozole, ARX788, ARX788 + Cemiplimab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, Cemiplimab, Cemiplimab plus REGN3767, Dan222 + Niraparib, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Durvalumab plus Olaparib, Endoxifen + Abemaciclib, GSK 5733584, GSK 5733584 + Dostarlimab, Ganetespib, Ivonescimab (20mg/kg Q3W), Lasofoxifene, MK-2206 with or without Trastuzumab, Neratinib, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, PLX3397, Patritumab and Trastuzumab, Pembrolizumab - 4 cycle, Pembrolizumab - 8 cycle, Pertuzumab and Trastuzumab, Rilvegostomig + TDXd, SD-101 + Pembrolizumab, SGN-LIV1A, SYD985 ([vic-]trastuzumab duocarmazine), Sarilumab + Cemiplimab + Paclitaxel, Standard Therapy, T-DM1 and Pertuzumab, Talazoparib plus Irinotecan, Trilaciclib with or without trastuzumab + pertuzumab, Tucatinib plus trastuzumab and pertuzumab, VV1 + Cemiplimab, Z-endoxifen, Zanidatamab
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 14, 2026, 4:15 PM EDT
Recruiting Not applicable Interventional

RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE

NCT06455085
Status at this site: Recruiting
View directory record Official record
Conditions
Fragility Fracture, Osteoporosis, Osteoporotic Fractures
Interventions
Augmented-Fracture Liaison Service Arm, Enhanced Usual Care Arm
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
2,634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
23
States / cities
Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 15, 2026, 10:50 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

NCT06544499
Status at this site: Recruiting
View directory record Official record
Conditions
Primary Immune Thrombocytopenia (ITP)
Interventions
Efgartigimod IV, Placebo IV
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Oceanside, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Sep 7, 2026, 11:11 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

NCT03711032
Site status not listed — check the official record
View directory record Official record
Conditions
High-risk Non-muscle Invasive Bladder Cancer
Interventions
BCG, Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2034
U.S. locations
44
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 15, 2026, 9:37 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

NCT03165734
Site status not listed — check the official record
View directory record Official record
Conditions
Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Primary Myelofibrosis
Interventions
Pacritinib, Physician's Choice medications
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 15, 2026, 12:15 PM EDT
Recruiting Phase 2 Interventional

REgulatory T Cell Therapy to Achieve Immunosuppression REduction

NCT06552169
Status at this site: Recruiting
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI
Drug · Biological
Lead sponsor
Singulera Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 14, 2026, 8:08 AM EDT

About this Mayo Clinic institution page

What this page lists
ClinicalTrials.gov records that list Mayo Clinic in Phoenix & Scottsdale, AZ as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Mayo Clinic at any site, browse by condition, or browse by U.S. city.